Squarepoint’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Squarepoint’s Portfolio MITO Stock Details MITO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-63,729	Closed	-$100K	–	3913
2021 Q1	$100K	Buy	+63,729	New	+$110K	﹤0.01%	2908

Other funds holding MITO

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBL

Sargent Bickham Lagudis Boulder, Colorado $1.22B AUM 14.94% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint's MITO Position: Q2 2021 in Review

Squarepoint sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q2 2021, closing a stake of 63,729 shares — an estimated $100K sold.

Squarepoint first reported a position in MITO in Q1 2021 and held it in 1 quarter. The position peaked at $100K in Q1 2021. 12 funds tracked by Wall St. Rank hold MITO as of Q2 2021.

Squarepoint reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 63,729 Stealth BioTherapeutics Corp. ADS shares in Q2 2021, an estimated $100K.
Squarepoint first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2021 and held it in 1 quarter.
Squarepoint's Stealth BioTherapeutics Corp. ADS position peaked at $100K in Q1 2021.
12 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.